PMID-35625682 – PNC-27 Chimeric Peptide Membrane Pore Formation
Bowne WB, Michl J, Sookraj KA, et al. PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis. Biomedicines. 2022;10(6):1258.
Quick Reference
| Property | Value |
|---|---|
| PMID | 35625682 |
| DOI | 10.3390/biomedicines10061258 |
| Year | 2022 |
| Journal | Biomedicines |
| Study Type | In vitro / Narrative Review |
| Evidence Level | V |
| Sample | Multiple cancer cell lines |
| Peptide(s) Studied | PNC-27, PNC-28 |
Key Findings
- PNC-27 is a 32-residue chimeric peptide containing p53 residues 12-26 fused to a penetratin cell-penetrating peptide (CPP) leader sequence
- The peptide binds to HDM-2 in a p53-like alpha-helical structure confirmed by NMR and molecular modeling
- Selective membrane-pore formation ("poptosis") occurs exclusively in cancer cells expressing membrane-associated HDM-2
- Normal cells lack membrane HDM-2 and are unaffected by PNC-27
- The mechanism is distinct from apoptosis — it is rapid necrotic cell death through transmembrane pore formation
- Comparison with PNC-28 (p53 residues 17-26) showed different HDM-2 binding characteristics
Study Design
Comprehensive review and new experimental data combining structural biology (NMR, circular dichroism), cell biology (confocal microscopy, LDH assays), and molecular modeling approaches. Multiple cancer cell lines tested including breast, pancreatic, melanoma, and leukemia lines alongside normal cell controls.
Limitations
- Primarily in vitro evidence
- No pharmacokinetic or in vivo efficacy data presented
- HDM-2 membrane localization mechanism still incompletely understood
- Single research group responsible for most PNC-27 work
Clinical Relevance
This comprehensive 2022 paper consolidates the structural and mechanistic understanding of PNC-27's anticancer activity. The term "poptosis" (peptide-induced transmembrane pore formation) was coined to describe this novel mechanism. The selectivity of the approach — cancer cells killed via membrane HDM-2, normal cells unaffected — makes PNC-27 a conceptually attractive candidate for targeted cancer therapy, though clinical translation remains early-stage.
Related
#research #in-vitro #narrative-review #PNC-27 #PNC-28 #evidence-level-V #cancer-therapeutic